SAN DIEGO, Aug. 21 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.
(NYSE: BMR) today announced that its underwriters have exercised their
over-allotment option in full to purchase an additional 1,042,500 shares of
common stock at the public offering price of $28.75 per share in connection
with BioMed's previously announced follow-on offering that priced on August
16, 2006. In total, the company sold 7,992,500 shares of common stock,
raising gross offering proceeds of approximately $229.8 million.
Raymond James & Associates, Inc. is the sole book-running manager for the
offering, with Morgan Stanley & Co. Incorporated, KeyBanc Capital Markets, a
division of McDonald Investments Inc., Wachovia Capital Markets, LLC, RBC
Capital Markets, Stifel, Nicolaus & Company, Incorporated, and Robert W. Baird
& Co. Incorporated acting as co-managers.
The registration statement relating to these securities has been declared
effective by the Securities and Exchange Commission. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy any of
BioMed's common stock, nor shall there be any sale of such common stock in any
state in which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of such state. The
offering of BioMed's common stock is made only by means of a prospectus and a
related prospectus supplement, copies of which may be obtained by contacting
Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on Providing Real Estate to the Life Science Industry(TM). The company's
tenants primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry, and its properties and primary
acquisition targets are generally located in markets with well established
reputations as centers for scientific research, including Boston, San Diego,
San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.
BioMed's real estate portfolio consists of 52 properties, representing 89
buildings with approximately 7.7 million rentable square feet in each of the
major life science markets in the United States. Additional information is
available at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: general risks affecting
the real estate industry (including, without limitation, the inability to
enter into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing and the use of debt to fund acquisitions and developments;
failure to manage effectively the company's growth and expansion into new
markets, or to complete or integrate acquisitions successfully; risks and
uncertainties affecting property development and construction; risks
associated with downturns in the national and local economies, increases in
interest rates, and volatility in the securities markets; potential liability
for uninsured losses and environmental contamination; risks associated with
the company's potential failure to qualify as a REIT under the Internal
Revenue Code of 1986, as amended, and possible adverse changes in tax and
environmental laws; and risks associated with the company's dependence on key
personnel whose continued service is not guaranteed. For a further list and
description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
BioMed Realty Trust, Inc.
Chief Financial Officer of BioMed Realty Trust,